Synvista
Therapeutics, Inc.
221
West Grand Avenue
Montvale,
New Jersey 07645
VIA
EDGAR
Securities
and Exchange Commission
100 F
Street, NE
Washington,
D.C. 20549
|
|
Re:
|
Synvista
Therapeutics, Inc.
|
Registration Statement on
Form S-3 (File No. 333-150875)
Ladies
and Gentlemen:
Pursuant to Rule 477 promulgated
under the Securities Act of 1933, as amended, Synvista Therapeutics, Inc. (the
“Company”) hereby requests that the Securities and Exchange Commission (the
“Commission”) consent to the withdrawal of the Company’s Registration Statement
on Form S-3 (File No. 333-150875) (the “Registration Statement”), which was
filed with the Commission on May 13, 2008.
The Registration Statement was filed
in connection with the registration for resale of 643,918 shares of the
Company’s common stock, par value $0.01 per share (the “Common Stock”) issued in
connection with a private placement. The Company hereby requests
withdrawal of the Registration Statement because the Company intends to
voluntarily delist
its Common Stock from trading on the NYSE Alternext US LLC and voluntarily
terminate the registration of its Common Stock under the Securities Exchange Act
of 1934, as amended. The Registration Statement has not been declared
effective by the Commission and no securities have been sold under the
Registration Statement.
Please contact our counsel, Megan N.
Gates, Esq., of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., at (617)
348-4443 with any questions concerning this request.
|
|
Sincerely,
|
|
|
|
|
|
|
|
|
/s/
Noah Berkowitz, M.D., Ph.D.
|
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
|
President
and Chief Executive Officer
|